Please try another search
For the nine months ended 31 March 2017, Nexvet Biopharma plc revenues was not reported. Net loss increased 7% to $16.5M. Higher net loss reflects Payroll and related - Balancing value increase of 53% to $4.8M (expense), Exchange gain (loss) decrease from $151K (income) to $958K (expense), Stock-based Compensation in R&D increase of 60% to $911K (expense). Basic Earnings per Share excluding Extraordinary Items decreased from -$1.34 to -$1.41.
Period Ending: | Mar 31, 2017 | Dec 31, 2016 | Sep 30, 2016 | Jun 30, 2016 |
---|---|---|---|---|
Total Revenue | 0 | 0 | 0 | 0 |
Gross Profit | ||||
Operating Income | -7.19 | -5.16 | -5.7 | -5.07 |
Net Income | -6.02 | -5.41 | -5.09 | -3.97 |
Period Ending: | Mar 31, 2017 | Dec 31, 2016 | Sep 30, 2016 | Jun 30, 2016 |
---|---|---|---|---|
Total Assets | 24.75 | 29.01 | 34.43 | 40.32 |
Total Liabilities | 3.83 | 2.92 | 3.83 | 5.19 |
Total Equity | 20.91 | 26.09 | 30.6 | 35.14 |
Period Ending: | Mar 31, 2017 | Dec 31, 2016 | Sep 30, 2016 | Jun 30, 2016 |
---|---|---|---|---|
Period Length: | 9 Months | 6 Months | 3 Months | 12 Months |
Cash From Operating Activities | -16.76 | -10.97 | -6.38 | -14.78 |
Cash From Investing Activities | -0.86 | -0.82 | -0.55 | -4.99 |
Cash From Financing Activities | 0.04 | 0.02 | 0.02 | 0.02 |
Net Change in Cash | -16.96 | -11 | -6.93 | -20.55 |
Unlock access to over 1000 metrics with InvestingPro
View advanced insights on financial statements, including growth rates and metrics that provide an in-depth view of the company's historical and forecasted financial performance.
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review